A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
BeOne Medicines
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Incyte Corporation
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Novartis
Alterome Therapeutics, Inc.
Verastem, Inc.
Pfizer